ProCE Banner Activity

Phase II IFM 2013-01: Pomalidomide/Cyclophosphamide/Dexamethasone in Relapsed Multiple Myeloma

Slideset Download
Conference Coverage
In evaluable patients who relapsed following initial RVD therapy (with or without upfront ASCT), 4 cycles of PCD yielded an ORR of 85% with 95% of transplant-naive patients proceeding to a first ASCT.

Released: December 12, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology